P-102. Changes in immunologic parameters following the addition of fostemsavir in virally suppressed immune non-responders living with HIV-the RECOVER study

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Charlotte-Paige Rolle, Jamie Castano, Vu Nguyen, Federico Hinestrosa, Edwin DeJesus
DOI: 10.1093/ofid/ofaf695.331
Cited by: 0

Abstract

Abstract Background Fostemsavir (FTR) is a pre-attachment inhibitor that binds directly to viral gp120 preventing HIV interaction with the host immune cell. This unique mechanism may drive the robust CD4+ T-cell recovery seen in the BRIGHTE study. Here, we evaluate changes in immunologic parameters following addition of FTR to antiretroviral (ARV) regimens among virally suppressed immune non-responders (INRs) through 48 weeks. Methods RECOVER (NCT05220358) is an ongoing, open-label clinical trial that enrolled adult INRs defined as those with HIV-1 RNA

Fields of Study & Subjects

HIV Research and Treatment HIV/AIDS drug development and treatment HIV-related health complications and treatments

Publication details

Journal / source
Open Forum Infectious Diseases
Volume
13
Issue
Supplement_1
Publication date
1 January 2026
Language
EN